AMNEAL PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $11.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $11.48M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$1.42M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$4.85M, a 158.58% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$8.45M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$45.22M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$33.16M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$43.05M, a 223.43% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $34.88M, a 108.63% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.48M 10-Q · filed 2026-08-06 | $10.06M 10-Q · filed 2026-08-06 | $5.22M derived: sum of 3 quarters · filed 2026-08-06 | -$3.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.42M 10-Q · filed 2026-05-07 | -$6.27M derived: sum of 2 quarters · filed 2026-05-07 | -$14.72M derived: sum of 3 quarters · filed 2026-05-07 | -$26.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$13.30M derived: sum of 2 quarters · filed 2026-02-27 | -$24.99M derived: sum of 3 quarters · filed 2026-08-06 | -$45.22M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$8.45M 10-Q · filed 2025-11-06 | -$20.14M derived: sum of 2 quarters · filed 2026-08-06 | -$40.37M 10-Q · filed 2025-11-06 | -$32.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$11.69M 10-Q · filed 2026-08-06 | -$31.92M 10-Q · filed 2026-08-06 | -$23.65M derived: sum of 3 quarters · filed 2026-08-06 | -$67.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$20.23M 10-Q · filed 2026-05-07 | -$11.96M derived: sum of 2 quarters · filed 2026-05-07 | -$55.30M derived: sum of 3 quarters · filed 2026-05-07 | -$62.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$35.07M derived: sum of 2 quarters · filed 2026-02-27 | -$41.80M derived: sum of 3 quarters · filed 2026-02-27 | -$33.16M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$43.35M 10-Q · filed 2025-11-06 | -$50.07M derived: sum of 2 quarters · filed 2025-11-06 | -$41.43M 10-Q · filed 2025-11-06 | -$78.33M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$6.72M 10-Q · filed 2025-08-07 | $1.91M 10-Q · filed 2025-08-07 | -$34.99M derived: sum of 3 quarters · filed 2026-02-27 | -$39.21M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $8.64M 10-Q · filed 2025-05-07 | -$28.26M derived: sum of 2 quarters · filed 2026-02-27 | -$32.48M derived: sum of 3 quarters · filed 2026-02-27 | -$28.17M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$36.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$41.12M derived: sum of 2 quarters · filed 2026-02-27 | -$36.81M derived: sum of 3 quarters · filed 2026-02-27 | -$43.05M 10-K · filed 2026-02-27 |
| 2023-09-30 | -$4.22M 10-Q · filed 2024-11-12 | $91.00K derived: sum of 2 quarters · filed 2024-11-12 | -$6.15M 10-Q · filed 2024-11-12 | -$8.75M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $4.31M 10-Q · filed 2024-08-09 | -$1.93M 10-Q · filed 2024-08-09 | -$4.53M derived: sum of 3 quarters · filed 2025-02-28 | $7.14M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$6.24M 10-Q · filed 2024-05-08 | -$8.84M derived: sum of 2 quarters · filed 2025-02-28 | $2.83M derived: sum of 3 quarters · filed 2025-02-28 | $4.05M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $9.07M derived: sum of 2 quarters · filed 2025-02-28 | $10.29M derived: sum of 3 quarters · filed 2025-02-28 | $34.88M 10-K · filed 2025-02-28 |
| 2022-09-30 | $11.67M 10-Q · filed 2023-11-09 | $12.89M derived: sum of 2 quarters · filed 2023-11-09 | $37.48M 10-Q · filed 2023-11-09 | $45.89M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $1.22M 10-Q · filed 2023-08-08 | $25.81M 10-Q · filed 2023-08-08 | $34.22M derived: sum of 3 quarters · filed 2024-03-14 | $34.98M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $24.59M 10-Q · filed 2023-05-09 | $33.00M derived: sum of 2 quarters · filed 2024-03-14 | $33.77M derived: sum of 3 quarters · filed 2024-03-14 | $34.20M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $8.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $9.18M derived: sum of 2 quarters · filed 2024-03-14 | $9.61M derived: sum of 3 quarters · filed 2024-03-14 | $16.72M 10-K · filed 2024-03-14 |
| 2021-09-30 | $766.00K 10-Q · filed 2022-11-07 | $1.20M derived: sum of 2 quarters · filed 2022-11-07 | $8.31M 10-Q · filed 2022-11-07 | $8.31M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $438.00K 10-Q · filed 2022-08-08 | $7.54M 10-Q · filed 2022-08-08 | $7.54M derived: sum of 3 quarters · filed 2023-03-03 | $5.95M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $7.10M 10-Q · filed 2022-05-06 | $7.11M derived: sum of 2 quarters · filed 2023-03-03 | $5.51M derived: sum of 3 quarters · filed 2023-03-03 | -$762.00K derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$1.60M derived: sum of 2 quarters · filed 2023-03-03 | -$7.87M derived: sum of 3 quarters · filed 2023-03-03 | -$41.20M 10-K · filed 2023-03-03 |
| 2020-09-30 | -$1.60M 10-Q · filed 2021-11-08 | -$7.87M derived: sum of 2 quarters · filed 2021-11-08 | -$41.20M 10-Q · filed 2021-11-08 | -$35.93M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$6.27M 10-Q · filed 2021-08-09 | -$39.61M 10-Q · filed 2021-08-09 | -$34.33M derived: sum of 3 quarters · filed 2022-03-01 | -$32.15M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$33.34M 10-Q · filed 2021-05-07 | -$28.06M derived: sum of 2 quarters · filed 2022-03-01 | -$25.88M derived: sum of 3 quarters · filed 2022-03-01 | -$28.52M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $7.46M derived: sum of 2 quarters · filed 2022-03-01 | $4.81M derived: sum of 3 quarters · filed 2022-03-01 | $8.49M 10-K · filed 2022-03-01 |
| 2019-09-30 | $2.18M 10-Q · filed 2020-11-06 | -$462.00K derived: sum of 2 quarters · filed 2020-11-06 | $3.22M 10-Q · filed 2020-11-06 | $5.36M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$2.65M 10-Q · filed 2020-08-06 | $1.04M 10-Q · filed 2020-08-06 | $3.17M derived: sum of 3 quarters · filed 2021-03-01 | -$211.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $3.68M 10-Q · filed 2020-05-11 | $5.82M derived: sum of 2 quarters · filed 2021-03-01 | $2.44M derived: sum of 3 quarters · filed 2021-03-01 | $1.26M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$1.25M derived: sum of 2 quarters · filed 2021-03-01 | -$2.42M derived: sum of 3 quarters · filed 2021-03-01 | -$2.42M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$3.38M 10-Q · filed 2019-11-07 | -$4.55M derived: sum of 2 quarters · filed 2019-11-07 | -$4.55M 10-Q · filed 2019-11-07 | -$4.55M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$1.17M 10-Q · filed 2019-08-05 | -$1.17M 10-Q · filed 2019-08-05 | -$1.17M derived: sum of 3 quarters · filed 2020-03-02 | -$1.17M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 | ||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |